Intracellulær sjekkpunkthemmer for kreftterapi

Offentlig prosjektsammendrag

Cellmover AS is a biotech company dedicated to developing cutting-edge immunotherapies for cancer. Our goal is to develop a nanobody-based checkpoint inhibitor that act intracellularly to disrupt signaling from inhibitory receptors in T cells. This is a completely new approach to block immune checkpoint proteins, in contrast to current state-of-art inhibitors that work extracellularly. Intracellular inhibitors may overcome resistance mechanisms that limit the efficacy of current extracellular checkpoint inhibitors, providing new therapeutic options for patients who do not respond to existing treatments. To achieve this, we will combine nanobody engineering approaches for efficient targeting and intracellular delivery, in vitro and in vivo models to test efficacy, ADMET studies and advanced computational models to predict pharmacokinetics, and if successful bring the nanobody candidate to clinical phase I.